[Nitric oxide inhalation in newborn infants with pulmonary hypertension].
Nitric oxide (NO) is an important endogenous vasodilator. NO, produced in the endothelial cell, causes vasodilation by relaxation of the vascular smooth muscle cell. Inhalation of NO plays a role in the treatment of persistent pulmonary hypertension of the newborn, a syndrome with considerable morbidity and mortality. NO inhalation specifically leads to pulmonary vasodilation without systemic hypotension, since NO binds avidly to haemoglobin. Neonates with pulmonary hypertension associated with lung hypoplasia, meconium aspiration syndrome, infantile inspiratory distress syndrome due to surfactant deficiency, and sepsis have been treated with inhaled NO. Literature data on NO inhalation and experience in our units with NO inhalation show an improvement in arterial oxygen tension and a decreased need for extracorporeal membrane oxygenation, but no reduction in mortality. NO toxicity as a result of NO inhalation in the newborn has not been reported yet.
de Beaufort
A J
AJ
Academisch Ziekenhuis, afd. Neonatologie, Leiden.
Slot
H M
HM
van Bel
F
F
D000280:Administration, Inhalation; D015199:Extracorporeal Membrane Oxygenation; D006801:Humans; D007231:Infant, Newborn; D008168:Lung / Q000002:abnormalities; D008471:Meconium Aspiration Syndrome / Q000188:drug therapy; D009569:Nitric Oxide / Q000008:administration & dosage* / Q000494:pharmacology; D010547:Persistent Fetal Circulation Syndrome / Q000188:drug therapy* / Q000628:therapy; D011014:Pneumonia / Q000188:drug therapy; D011652:Pulmonary Circulation / Q000187:drug effects; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy; D014664:Vasodilation / Q000187:drug effects
D009569:Nitric Oxide